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ABSTRACT 
Background The high cost and insufficient supply of human papillomavirus (HPV) 
vaccines have slowed the pace of controlling cervical cancer. A phase 3 clinical trial 
was conducted to evaluate the efficacy, safety and immunogenicity of a novel 
Escherichia coli-produced bivalent HPV-16/18 vaccine. 
Methods A multi-centre, randomized, double-blind trial started on November 22, 
2012, in China. In total, 7372 eligible women aged 18-45 years were age-stratified 
and randomly assigned to receiving 3 doses of the test or control (hepatitis E) vaccine 
at months 0, 1 and 6. Co-primary endpoints included high-grade genital lesions and 
persistent infection (over 6 months) associated with HPV-16/18. The primary analysis 
was performed on a per-protocol susceptible population of individuals who were 
negative for relevant HPV type-specific neutralizing antibodies (at day 0) and DNA 
(at day 0 through month 7) and who received 3 doses of the vaccine. This report 
presents data from a pre-specified interim analysis used for regulatory submission. 
Results In the per-protocol cohort, the efficacies against high-grade genital lesions 
and persistent infection were 100.0% (95% confidence interval [CI] = 55.6% to 
100.0%, 0/3306 in the vaccine group vs. 10/3296 in the control group) and 97.8% 
(95% CI = 87.1% to 99.9%, 1/3240 vs. 45/3246), respectively. The side effects were 
mild. No vaccine-related serious adverse events were noted. Robust antibody 
responses for both types were induced and persisted for at least 42 months. 
Conclusions The Escherichia coli-produced HPV-16/18 vaccine is well tolerated and 
highly efficacious against HPV-16/18 associated high-grade genital lesions and 
persistent infection in women. 
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Human papillomavirus (HPV) is the most common viral infection of the 
genital tract (1). Persistent infection with carcinogenic types may lead to precancerous 
lesions with the possibility of progressing to cancer (2). Globally, HPV types 16 and 
18 are responsible for approximately 70% of cervical cancer cases (3). A large 
majority (>85%) of cervical cancer cases (445000 annually) occur in developing 
regions with limited resources, where cervical cancer accounts for ~12% of all 
cancers in women (4). Three highly efficacious HPV vaccines are currently 
commercialized and are listed in national immunization programmes in over 70 
countries (4). These efforts have led to notable accomplishments, including a 
continuing reduction in the prevalence of HPV-16/18 and related precancerous lesions 
(5-7). Unfortunately, the high cost and insufficient supply of the current vaccines have 
greatly slowed the pace of their implementation in lower-income countries for the 
WHO call to action to eliminate cervical cancer (8, 9).  
The currently marketed HPV vaccines, HPV-6/11/16/18 quadrivalent vaccine 
(10), HPV-6/11/16/18/31/33/45/52/58 9-valent vaccine (11) and HPV-16/18 bivalent 
vaccine (12), are all composed of L1 virus-like particles (VLPs) produced in 
eukaryotic cells as the immunogens. Notably, an Escherichia coli (E. coli)-produced 
bivalent HPV-16/18 L1 VLP vaccine candidate was shown to be safe and 
immunogenic in women (13, 14). The aim of the present phase 3 trial was to assess 
the efficacy, safety and immunogenicity of this HPV vaccine in women. 
 
Methods 
Study design and participants 
This study is a multi-centre, randomized, double-blind, controlled (hepatitis E 
vaccine) clinical trial in adult women. Independent Ethics Committee approvals were 
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obtained, and the study was conducted in accordance with Good Clinical Practice.  
Participants were recruited at 5 study sites in China. Women were eligible to 
participate in the study if they were healthy, nonpregnant, and aged 18-45 years 
(Supplementary Table 1). Written informed consent was obtained from all 
participants (ClinicalTrials.gov, NCT01735006). At each site, the participants were 
age-stratified (into two groups: 18-26 and 27-45 years) and randomly assigned (1:1) 
to receive either the HPV-16/18 vaccine or the control vaccine, which were identical 
in appearance, according to a permuted-block randomization list (with 12 codes per 
block) provided by an independent statistician.  
The co-primary efficacy endpoints included the following: histopathologically 
confirmed HPV-16 and/or HPV-18 related grade 2 or higher cervical intraepithelial 
neoplasia (CIN), vulvar intraepithelial neoplasia (VIN) and/or vaginal intraepithelial 
neoplasia (VaIN) (the pathological endpoint); and persistent HPV-16 and/or HPV-18 
infection (over 6 months, > 150 days) (the persistent infection endpoint). 
 
Vaccines 
The bivalent HPV test vaccine was a mixture of two aluminium hydroxide adjuvant-
absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli (13-15). 
The vaccine formulation contained 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLP, 
suspended in 0.5 mL of buffered saline and 208 μg of aluminium adjuvant. The 
control vaccine was a commercialized recombinant hepatitis E vaccine (HepE) 
(Xiamen Innovax, Xiamen, China) (16, 17). 
 
Vaccination and follow-up visits 
Three doses of the HPV vaccine or control vaccine were administered intramuscularly 
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at day 0, month 1 (28 to 60 days) and month 6 (150 to 240 days). All the participants 
were trained to record all adverse events (AEs) occurring within one month after each 
injection in diary cards. Throughout the trial, all serious adverse events (SAEs) and 
pregnancy outcomes were requested to be reported. Serum samples were collected at 
day 0 and at month 7 for all the participants. Clinical follow-up visits included a 
gynaecologic examination with collection of endocervical swab samples for 
Papanicolaou testing and HPV DNA testing. The visits were scheduled at day 0 and 
months 7, 12, 18, 24, 30, 42, 54 and 66 for all participants. At the time of the current 
interim analysis, data were available up to month 42. 
 
Efficacy and immunogenicity endpoint assessments 
Cytology, histopathology and HPV DNA testing were performed in a central 
laboratory at the Cancer Institute of the Chinese Academy of Medical Sciences 
(CICAMS). Cytology results were reported according to the Bethesda system-2001 
(18, 19). Histopathological analysis was performed blindly by an independent 
pathology panel at CICAMS. Details of the colposcopy referral and biopsy algorithm 
were described in Supplementary Figures 1. The final judgements of endpoint 
events were made by the gynaecologist and the pathologist in the independent data 
and safety monitoring board (DSMB), who blindly reviewed the data for each case 
proposed by the principal investigator (Supplementary Methods).  
HPV DNA testing was first performed using the HPV DNA enzyme 
immunoassay method (DEIA) (Labo Biomedical Products, Netherlands). Samples 
with positive or borderline (defined per the manual of the kit) findings were further 
typed by a reverse hybridization line probe assay (Labo Biomedical Products, 
Netherlands, based on licensed Innogenetics LiPA technology), and by HPV-16- and 
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HPV-18-specific polymerase chain reactions (HPV TS16/18, Labo Biomedical 
Products, Netherlands) (Supplementary Figure 2). Detection of the high-risk type of 
HPV in paraffin-embedded tissue specimens was considered to be associated with 
lesions. If more than one high-risk type of HPV was found in the paraffin section, 
causality was confirmed if the same HPV type was detected in the closest preceding 
exfoliated cell samples. Otherwise, all high-risk HPV types presenting in the lesion 
were considered to be associated with that lesion.  
Immunogenicity was analysed in the per-protocol subset for immunogenicity 
(PPS-I), which included all participants who complied with the protocol, were 
negative for IgG antibody against the relevant types of HPV at entry, were negative 
for the relevant types of HPV DNA at day 0 through month 7, and had IgG antibody 
results at month 7. The immune persistence of the vaccine was assessed in a subcohort 
of PPS-I (PPS-P), containing participants from one selected study site who had IgG 
antibody data available at any of the follow-up visits after month 7. IgG antibodies 
against HPV-16 and HPV-18 at day 0 and month 7 were tested by an enzyme-linked 
immunosorbent assay (ELISA) using E. coli-expressed L1 VLPs of either type as 
coating antigens (20). The positive samples were further quantified using references 
traceable to the WHO international standards for antibodies against HPV-16 (NIBSC 
code 05/134) or HPV-18 (NIBSC code 10/140), expressed in international units (IU). 
The lower detection limits of the assays were 3.1 IU/mL for HPV-16 antibodies and 
2.0 IU/mL for HPV-18 antibodies. For calculating the geometric mean concentration 
(GMC), antibody titres below the lower detection limit of the assay were given an 
arbitrary value of half the cutoff value. To determine the previous or prevalent 
infection at entry, neutralizing antibodies against HPV-16 or 18 on day 0 were tested 
using the pseudovirion-based neutralization assay (PBNA) (20, 21), which would 
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preserve the power of the study and avoid over-excluding participants from the per-
protocol set (PPS) cohort.  
 
Statistical analysis 
The study was designed based on preventive efficacy against the pathological and 
persistent infection endpoints related to HPV-16 and/or -18 (HPV-16/18). Efficacy 
and confidence intervals (CIs) were calculated on the basis of the observed difference 
in event rates using accrued person time as the denominator. An exact conditional 
procedure was used to evaluate efficacy under the assumption that the numbers of 
cases with endpoint events in the vaccine and control groups were independent 
Poisson random variables (22).  
Efficacy analyses were mainly based on the PPS (PPS-E for pathological 
endpoints and PPS-PI for persistent infection endpoints). The PPS cohort contained 
participants who: were susceptible to infection by a relevant type of HPV (susceptible 
participants, i.e., negative for the corresponding type of neutralizing antibody on day 
0 and negative for the corresponding type of HPV DNA from day 0 through month 7); 
had received three doses of the test or control vaccine; had at least one effective 
endpoint follow-up visit after month 7; and had no severe protocol violation. To 
estimate vaccine efficacy in a population with less perfect compliance, a modified 
intention-to-treat analysis (mITT, mITT-E for pathological endpoint, and mITT-PI for 
persistent infection endpoint) was conducted on unrestricted susceptible participants 
who received at least one dose of the vaccine and were susceptible to infection by a 
relevant type of HPV. Case counting for the PPS and mITT analyses started from 
month 7. ITT analysis included those who received at least one dose, and baseline 
cases (at entry) were excluded. 
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The null hypotheses for the pathological endpoint and persistent infection, 
with an overall two-tailed alpha of 0.05, are that the lower limit of the 95% CI of 
efficacy is not higher than 0% and not higher than 25%, respectively. Two planned 
interim efficacy analyses were triggered on the basis of a fixed number of primary 
endpoint events detected in the PPS cohort. For the persistent infection endpoint, the 
interim efficacy analysis with a two-tailed alpha of 0.025 was triggered when at least 
29 cases of persistent HPV-16/18 infection were identified. For the pathological 
endpoint, the calculated nominal alpha value was used to control the probability of 
type I error below 0.05 (two-tailed) based on the O’Brien-Fleming alpha dissipation 
function (23). The interim analysis with a two-tailed alpha value of 0.004 was 
performed when at least 9 CIN2+ cases associated with HPV-16/18 infection were 
detected. 
To ensure adequate power for the interim analysis (a power of 80% with a 
two-sided alpha of 0.004) and the final analysis (a power of at least 90% with a two-
sided alpha of 0.049) for a true vaccine efficacy of 85 to 90%, with an anticipated 
annual event rate of 0.2% for pathological endpoint, a total of 4327 per-protocol 
participants were required for the study. To compensate for dropouts, a total sample 
size of >6000 was needed. 
When 10 CIN2+ cases related to HPV-16/18 were identified in the per-
protocol cohort through the visits by February 28, 2017, an interim analysis was 
performed by the DSMB independently. Based on the positive suggestions given by 
the DSMB, interim analyses for licensing purposes were conducted, and the major 
findings are reported here. 
Analyses for immunogenicity were performed in the PPS-P and PPS-I cohorts. 
Safety analyses were performed for all the participants who received at least one 
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injection. 
Data from different sites involved in this trial were combined for analysis by 
using SAS software (version 9.1). All reported p values are two-sided with an alpha 
value of 0.05, except for those specifically indicated.  
 
Results 
In total, 8827 women attended the enrolment visit between November 22, 2012, and 
April 1, 2013. Of these women, 7372 met the eligibility requirements and were 
randomly assigned to receive the test vaccine (n = 3689) or the control vaccine (n = 
3683) (Figure 1). 95.1% of women received all 3 doses of the assigned regimens 
(Supplementary Table 2). Baseline characteristics were similarly distributed 
between groups (Table 1). 81.4% and 89.4% of the participants were susceptible to 
HPV-16 and HPV-18 infections, respectively, i.e., negative for type-specific 
neutralizing antibody on day 0 and negative for the relevant type of HPV DNA from 
day 0 through month 7. 
The participants were followed for an average of 3.3 years. In the PPS cohort 
for the pathological endpoint (PPS-E), which included 6602 of 7372 women who 
underwent randomization (89.6%), 10 women in total, all in the control group, 
developed high-grade genital lesions associated with HPV-16/18 (seven CIN2 cases 
and three CIN3 cases). The HPV vaccine prevented 100.0% (95% CI, 55.6 to 100.0, 
0/3306 in the vaccine group vs. 10/3296 in the control group) of HPV-16/18 related 
high-grade genital lesions in this population. Furthermore, the vaccine provided an 
efficacy of 97.8% (95% CI, 87.1 to 99.9, 1/3240 vs. 45/3246) against persistent 
infection (over 6 months) associated with HPV-16/18 in the per-protocol cohorts 
(PPS-PI) (Table 2). The robustness of the vaccine efficacies against both co-primary 
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endpoints were further confirmed in the Kaplan-Meier plots (Figure 2). The 
percentage of women completing all three vaccinations was very high, so the per-
protocol and mITT analyses are similar (Table 2).  
Additionally, the vaccine statistically significantly lowered the risk of incident 
infection (Table 2) and cytological abnormalities of the cervix related to HPV-16/18 
(Supplementary Table 4). For the non-vaccine types HPV-31/33/45, the vaccine 
decreased persistent infections related to these types as a combined group (47.2%, 
95% CI, 0.0 to 73.1, Table 3), although this difference did not reach statistical 
significance (P = 0.05). The vaccine showed no effects on reducing genital lesions or 
clearing the prevalent infection for women with detectable HPV DNA for the vaccine 
types at baseline (Supplementary Table 5). Among those who received a single dose 
in the mITT cohort, only 1 persistent infection and 2 incident infection events related 
to HPV 16/18 occurred, and all of them were in the control group. 
One month after the third dose of the HPV vaccine, all 2302 baseline 
seronegative women seroconverted for anti-HPV-16 (100.0%); the mean IgG 
antibody level (GMC) was 790.4 IU/mL (95% CI, 767.5 to 813.9), which was over 
100 times higher than the mean antibody level acquired from natural infection (7.1 
IU/mL, calculated from the antibody level at day 0 of 367 seropositive participants at 
entry). For HPV-18, the seroconversion rate was 99.9% (2799/2802), with a GMC of 
267.9 IU/mL (95% CI, 260.4 to 275.6), which was over 50 times higher than the mean 
antibody level acquired from natural infection (4.7 IU/mL, the GMC of day 0 from 
149 seropositive participants at entry). The vaccine-induced IgG antibodies decreased 
~8 times (anti-HPV-16) or ~10 times (anti-HPV-18) during the first year after the 
third vaccination and then remained relatively stable to month 42 at levels of ~100 
IU/mL (anti-HPV-16) and ~25 IU/mL (anti-HPV-18) (Figure 3). 
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Total AEs, local or systemic reactions, and unsolicited events occurred at 
similar rates between groups (Table 4, Supplementary Table 6). Pain at the injection 
site (34.0%) and fever (>37.0 °C, 35.1%) were the most common reactions that 
occurred in the vaccine group. Most AEs were mild. The participants reporting SAEs 
were distributed similarly between groups, and none of the SAEs were considered to 
be related to vaccination (Supplementary Table 7).  
Pregnancy was reported in 977 women from the vaccine group (26.5%) and 
981 women from the control group (26.7%) (Table 4). The proportions of women 
who became pregnant and their outcome profiles were similar for both groups. No 
congenital anomalies or pregnancy complications/abnormal events were associated 
with the vaccination in either group. 
 
Discussion 
Similar to the marketed HPV vaccines (10, 12, 24, 25), the candidate E. coli-produced 
HPV-16/18 vaccine almost entirely prevented high-grade genital lesions and 
persistent infection associated with the vaccine types of HPV in susceptible women. 
The vaccine was well tolerated; no SAEs related to vaccination were noted. 
Furthermore, robust vaccine-induced antibody responses for both types were detected 
in almost all participants who received three doses of the vaccine. 
The test vaccine demonstrated consistent high prevention efficacy against 
HPV-16/18 associated CIN2+ lesions, CIN1+ lesions and persistent infection in 
susceptible women. Additionally, the vaccine statistically significantly lowered the 
risk of incident infection as well as cytological abnormalities of the cervix related to 
HPV-16/18. Similar to the three licensed HPV vaccines, the test vaccine showed no 
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effect on reducing genital lesions or clearing the prevalent infections for women with 
detectable HPV DNA of the vaccine types at baseline (11, 26, 27). 
Limited by the lower rate and longer time needed to induce high-grade lesions 
for HPV-18 than HPV-16 (28-30), the vaccine efficacy against the type-specific 
CIN2+ endpoint was confirmed for HPV-16 but not HPV-18 in this interim analysis. 
Nevertheless, the test vaccine demonstrates consistent high efficacy for preventing 
HPV-18 associated persistent infection, incident infection, and cytological 
abnormalities. Thus, the E. coli-produced HPV-16/18 vaccine is probably as effective 
at preventing high-grade lesions related to HPV-18 as it is at preventing high-grade 
lesions related to HPV-16. 
The majority of the side effects of the test vaccine were mild. No SAEs were 
related to vaccination in either group. No meaningful clinical safety concerns 
regarding post-vaccination pregnancy or infant outcomes were raised. These findings 
confirm the well-tolerated profiles of HPV L1-VLP vaccines, which have been well-
established for the available HPV vaccines (31). 
The test HPV vaccine induced robust and durable antibody responses to both 
types in the vaccine. The seroconversion rates approached or equalled 100%. Peak 
IgG GMCs at one month after the third dose were over 100-fold (for HPV-16) and 50-
fold (for HPV-18) higher than those induced by natural infection, then declined 
approximately 10-fold one year later and were stable over the next two years. The 
remaining antibody titres at month 42 were 15-fold or 5-fold higher than those after 
natural infection for type 16 or 18, respectively. A similar serological pattern was also 
noted for Gardasil (32). The priority target population for HPV vaccination is young 
adolescents, in which population a two-dose schedule was recommended. Immuno-
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bridging data for the test HPV vaccine in girls are available, which are encouraging 
(33). 
Our study is not without limitations. Although encouraging cross-protection 
effects on infection caused by some non-vaccine types of HPV were observed, the 
study did not have enough power due to the small number of cases, and more follow-
up data are needed for the cross-protection analysis. Further studies such as head-to-
head comparison studies with other HPV vaccines and bridging studies on girls of 
other races, would be valuable for future implementation of this vaccine. 
As a robust protein expression host, E. coli has the characteristics of 
inexpensive culturing, high expression levels, short turnaround time and easy scale-up 
if the protein can correctly auto-folded (34). Hence, E. coli has been widely used in 
the biopharmaceutical industry for producing recombinant proteins for therapeutic 
use. However, the formation of specific conformational structures is essential for 
ensuring the efficacy of VLP-based vaccines, which is not easily achieved in many 
cases. To date, only one E. coli-expressed and VLP-based vaccine has been 
commercialized, which is well tolerated and high efficacious against hepatitis E (16, 
17). It is estimated that millions of doses of the final HPV-16/18 VLP stock solution 
can be obtained from one 500-litre fermentation through the current manufacturing 
process. 
In conclusion, the E. coli-produced bivalent HPV-16/18 vaccine is well 
tolerated and highly efficacious in preventing high-grade genital lesions and persistent 
infection associated with HPV-16/18. In addition to a potential new source of the 
cervical cancer preventive vaccine, the easy scale-up and low manufacturing cost of 
the E. coli-based manufacturing process is a promising improvement with regard to 
accessibility for resource-limited countries. 
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Tables 
 
Table 1. Baseline Characteristics of the Participants 
Characteristic 
Vaccine group 
No. (%) 
(N=3689) 
Control group 
No. (%) 
(N=3683) 
General   
Mean age, y (SD) 30.0±7.40 29.9±7.33 
Younger subgroup, age 18-26 y 1861 (50.4) 1862 (50.6) 
Senior subgroup, age 27-45 y 1828 (49.6) 1821 (49.4) 
Baseline HPV-associated findings   
HPV-16   
Detectable virus DNA from day 0 to month 7 141 (3.8) 138 (3.7) 
Detectable neutralizing antibodies on day 0 467 (12.7) 459 (12.5) 
Susceptible to infection* 2985 (80.9) 3013 (81.8) 
HPV-18   
Detectable virus DNA from day 0 to month 7 53 (1.4) 60 (1.6) 
Detectable neutralizing antibodies on day 0 186 (5.0) 180 (4.9) 
Susceptible to infection* 3300 (89.5) 3292 (89.4) 
Cytological findings at day 0   
Negative for intraepithelial lesion or malignancy 
(NILM) 
3341 (90.6) 3354 (91.1) 
Atypical squamous cells of undetermined significance 
(ASC-US) 
195 (5.3) 192 (5.2) 
Negative on Hybrid Capture-2 test 109 (3.0) 109 (3.0) 
Positive on Hybrid Capture-2 test 86 (2.3) 83 (2.3) 
Low-grade squamous intraepithelial lesion (LSIL) 108 (2.9) 96 (2.6) 
High-grade squamous intraepithelial lesion (HSIL) 31 (0.8) 26 (0.7) 
Atypical squamous cells cannot exclude high-grade 
lesion (ASC-H) 
4 (0.1) 10 (0.3) 
Adenocarcinoma in situ (AIS) 1 (0.03) 0 (0.0) 
Atypical glandular cells (AGC) 7 (0.2) 2 (0.05) 
Histopathological findings at day 0
†
    
Cervical intraepithelial neoplasia grade 1 (CIN1) 40 (1.1) 44 (1.2) 
Vaginal intraepithelial neoplasia grade 1 (VaIN1) 3 (0.08) 2 (0.05) 
Cervical intraepithelial neoplasia grade 2 (CIN2) 29 (0.8) 32 (0.9) 
Cervical intraepithelial neoplasia grade 3 (CIN3) 9 (0.2) 13 (0.4) 
Microinvasive carcinoma (MIC) 0 (0.0) 1 (0.03) 
Squamous cell carcinoma (SCC) 1 (0.03) 1 (0.03) 
* Susceptible to infection by a relevant type of HPV, i.e., negative for type-specific 
neutralizing antibodies on day 0 and negative for the relevant type of HPV DNA 
from day 0 to month 7. Missing data on neutralizing antibodies or DNA were not 
deemed negative. 
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† No cases of vaginal intraepithelial neoplasia grade 2 or higher (VaIN2+) or vulvar 
intraepithelial neoplasia (VIN) were diagnosed at entry.  
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Table 2. Vaccine efficacy against genital lesions, persistent infection, or incident infection associated with HPV-16 or HPV-18 
Endpoint 
Vaccine group Control group 
Vaccine 
efficacy, % 
(95% CI) 
P‡ Total 
participants 
Person-
years at 
risk* 
No. 
of 
cases 
Rate
†
 
Total 
participants 
Person-
years 
at risk* 
No. 
of 
cases 
Rate
†
 
Lesion of the cervix, vagina, and vulva 
related to HPV-16/18§ 
          
Participants in the per-protocol 
susceptible population (PPS-E) 
          
Lesion grade           
High grade 
(CIN2+/VIN2+/VaIN2+) 
3306 9119.9 0 0 3296 9079.3 10 0.1 100.0 (55.6-
100.0)|| 
.002 
Any grade 
(CIN1+/VIN1+/VaIN1+) 
3306 9119.9 0 0 3296 9075.7 14 0.2 100.0 (70.0-
100.0) 
<.001 
HPV type-specific high-grade lesion           
HPV-16 2885 7977.1 0 0 2911 8022.7 9 0.1 100.0 (49.0-
100.0) 
.004 
HPV-18 3175 8765.7 0 0 3153 8694.4 1 0.01 100.0 (-3768.3-
100.0) 
1.00 
Participants in the unrestricted susceptible 
population (mITT-E) 
          
Lesion grade           
High grade 
(CIN2+/VIN2+/VaIN2+) 
3386 9304.1 0 0 3386 9291.1 10 0.1 100.0 (55.4-
100.0) 
.002 
Any grade 
(CIN1+/VIN1+/VaIN1+) 
3386 9304.1 0 0 3386 9287.5 14 0.2 100.0 (69.9-
100.0) 
<.001 
HPV type-specific high-grade lesion           
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HPV-16 2943 8110.8 0 0 2972 8165.6 9 0.1 100.0 (49.0-
100.0) 
.004 
HPV-18 3252 8943.9 0 0 3239 8897.4 1 0.01 100.0 (-3779.7-
100.0) 
1.00 
Persistent infection ≥6-month duration           
Participants in the per-protocol susceptible 
population (PPS-PI) 
          
Related to HPV-16 or -18 3240 9026.5 1 0.01 3246 8904.9 45 0.5 97.8 (87.1-99.9) <.001 
Related to HPV-16 2833 7887.0 1 0.01 2863 7886.9 28 0.4 96.4 (78.4-99.9) <.001 
Related to HPV-18 3112 8687.7 0 0 3110 8595.7 19 0.2 100.0 (78.8-
100.0) 
<.001 
Participants in the unrestricted susceptible 
population (mITT-PI) 
          
Related to HPV-16 or -18 3313 9219.9 1 0.01 3330 9113.4 48 0.5 97.9 (88.0-99.9) <.001 
Related to HPV-16 2884 8020.5 1 0.01 2920 8026.7 30 0.4 96.7 (79.9-99.9) <.001 
Related to HPV-18 3182 8872.6 0 0 3190 8797.2 20 0.2 100.0 (79.9-
100.0) 
<.001 
Incident infection           
Participants in the per-protocol susceptible 
population (PPS-II) 
         
 
Related to HPV-16 or -18 3307 9059.1 44 0.5 3300 8952.0 144 1.6 69.8 (57.4-79.0) <.001 
Related to HPV-16 2886 7920.5 31 0.4 2914 7955.0 87 1.1 64.2 (45.5-77.1) <.001 
Related to HPV-18 3176 8729.6 14 0.2 3157 8628.8 66 0.8 79.0 (62.3-89.1) <.001 
Participants in the unrestricted susceptible 
population (mITT-II) 
         
 
Related to HPV-16 or -18 3388 9263.0 45 0.5 3391 9161.6 153 1.7 70.9 (59.2-79.6) <.001 
Related to HPV-16 2945 8064.6 32 0.4 2975 8096.4 91 1.1 64.7 (46.7-77.2) <.001 
Related to HPV-18 3253 8924.4 14 0.2 3244 8832.9 71 0.8 80.5 (65.1-89.8) <.001 
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* Person-years at risk was defined as the cumulative follow-up years of the at-risk participants at the indicated time point. CI : confidence 
interval;  
† The rate is the number of participants with the endpoint per 100 person-years at risk.  
‡ Fisher’s exact test was used to calculate the P values with two-sided test. 
§ HPV-16/18 associated AIS and cervical cancer were defined as the high-grade lesion endpoint.  
|| The 99.6% CI of the efficacy against HPV-16/18-related CIN2+/VIN2+/VaIN2+ in the PPS-E cohort is 14.2% to 100.0%.  
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Table 3. Vaccine cross-protection against carcinogenic HPV persistent infection (6 m) other than HPV-16/18 in the per-protocol cohort* 
HPV type 
Vaccine group Control group 
Vaccine efficacy 
% (95% CI) 
P§ No. of 
participants 
No. of 
events 
Person-
years at 
risk† 
Rate‡ 
No. of 
participants 
No. of 
events 
Person-
years at 
risk† 
Rate‡ 
HPV-31 3278 8 9151.3 0.1 3280 13 9092.0 0.1 38.9 (-59.1-78.0) 0.38 
HPV-33 3282 7 9159.7 0.1 3274 15 9072.3 0.2 53.8 (-20.4-84.1) 0.13 
HPV-35 3289 8 9180.8 0.1 3286 15 9116.2 0.2 47.0 (-33.1-80.6) 0.21 
HPV-39 3248 33 9011.2 0.4 3243 31 8952.0 0.3 -5.8 (-78.5-37.2) 0.90 
HPV-45 3299 1 9228.3 0.01 3298 5 9167.4 0.1 80.1 (-77.6-99.6) 0.22 
HPV-51 3225 41 8916.4 0.5 3218 28 8878.6 0.3 -45.8 (-144.8-
12.0) 
0.15 
HPV-52 3075 67 8455.1 0.8 3108 52 8521.9 0.6 -29.9 (-90.3-10.9) 0.20 
HPV-56 3257 31 9041.7 0.3 3266 29 9016.6 0.3 -6.6 (-83.3-37.8) 0.90 
HPV-58 3258 23 9059.5 0.3 3248 28 8978.3 0.3 18.6 (-46.6-55.2) 0.58 
HPV-59 3283 15 9157.8 0.2 3289 12 9125.8 0.1 -24.6 (-191.4-
45.6) 
0.70 
HPV-66 3261 22 9065.8 0.2 3263 26 9024.0 0.3 15.8 (-54.6-54.5) 0.67 
HPV-68 3257 25 9059.8 0.3 3257 20 9005.2 0.2 -24.2 (-135.9-
33.7) 
0.55 
HPV-31/33/45 3314 16 9223.4 0.2 3312 30 9135.8 0.3 47.2 (0.0-73.1) 0.05 
 
* Per-protocol cohort: included those who: were susceptible to infection by a relevant type of carcinogenic HPV other than HPV-16/18 
(negative for the corresponding type of HPV DNA from day 0 through month 7); had received three doses of the test or control vaccine; 
had an effective endpoint follow-up visit after month 7; and had no severe protocol violation. 
 27 
 
† Person-years at risk was defined as the cumulative follow-up years of the at-risk participants at the indicated time point. 
‡ The rate is the number of cases per 100 person-years at risk. 
§ Fisher’s exact test was used to calculate the P values with two-sided test. 
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Table 4. Safety outcomes* 
Adverse Events No. of adverse events (Rate, %)  
Vaccine group Control group 
No. of participants who received ≥ 1 injection 3691
†
 3681
†
 
Solicited local adverse events within 72 hours after 
each vaccination 
  
All local AEs 1396 (37.8) 1552 (42.2) 
Local AEs ≥ Grade 3 24 (0.7) 68 (1.8) 
All pain 1256 (34.0) 1328 (36.1) 
Pain ≥ Grade 3 0 (0) 0 (0) 
All induration 261 (7.1) 326 (8.9) 
Induration ≥ Grade 3 11 (0.3) 25 (0.7) 
All red 162 (4.4) 244 (6.6) 
Red ≥ Grade 3 6 (0.2) 40 (1.1) 
All swelling 160 (4.3) 282 (7.7) 
Swelling ≥ Grade 3 15 (0.4) 52 (1.4) 
All pruritus 163 (4.4) 377 (10.2) 
Pruritus ≥ Grade 3 0 (0) 0 (0) 
Solicited systemic adverse events within 72 hours 
after each vaccination 
  
All systemic AEs 1683 (45.6) 1701 (46.2) 
Systemic AEs ≥ Grade 3 8 (0.2) 5 (0.1) 
All fever 1296 (35.1) 1253 (34.0) 
Fever ≥ Grade 3 7 (0.2) 4 (0.1) 
All fatigue and weakness 275 (7.5) 282 (7.7) 
Fatigue and weakness ≥ Grade 3 0 (0) 1 (0.03) 
All headache 259 (7.0) 274 (7.4) 
Headache ≥ Grade 3 0 (0) 0 (0) 
All cough 189 (5.1) 217 (5.9) 
Cough ≥ Grade 3 0 (0) 0 (0) 
All myalgia 122 (3.3) 164 (4.5) 
Myalgia ≥ Grade 3 0 (0) 0 (0) 
All nausea 118 (3.2) 125 (3.4) 
Nausea ≥ Grade 3 0 (0) 0 (0) 
All diarrhoea 102 (2.8) 104 (2.8) 
Diarrhoea ≥ Grade 3 1 (0.03) 0 (0) 
All allergic reaction 40 (1.1) 62 (1.7) 
Allergic reaction ≥ Grade 3 0 (0) 0 (0) 
All vomiting 36 (1.0) 44 (1.2) 
Vomiting ≥ Grade 3 0 (0) 0 (0) 
Unsolicited events within 30 days after each 
vaccination
‡
 
  
All 1402 (38.0) 1380 (37.5) 
≥ Grade 3 19 (0.5) 23 (0.6) 
Serious adverse events during the entire study
§
   
Within 30 days after each vaccination   
All 21 (0.6) 22 (0.6) 
Death|| 1(0.03) 0 (0) 
During the entire study   
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All 205(5.6) 244(6.6) 
Death|| 3(0.08) 3(0.08) 
 
Pregnancy and pregnancy outcomes during the entire 
study 
  
Women becoming pregnant 977 (26.5) 981 (26.7) 
No. of pregnancy events
¶
 1187 1219 
Ongoing 4 (0.3) 7 (0.6) 
Normal delivery 554 (46.7)  613 (50.3) 
Spontaneous abortion 68 (5.7) 68 (5.6) 
Stillbirth 10 (0.8) 14 (1.1) 
Maternal complications 11 (0.9) 7 (0.6) 
Elective termination 540 (45.5) 510 (41.8) 
No. of infants# 556 615 
Normal infant 555 (99.8) # 613 (99.7) # 
Congenital anomaly 0 (0) 2 (0.3) ** 
Other complications or abnormality 1 (0.2) †† 0 (0) 
* Symptoms with a frequency greater than 1% in any group are listed. Grade 3 pain 
was defined as influencing daily activities or requiring multiple uses of narcotic 
analgesics. Grade 3 induration, redness, and swelling were defined as having a 
diameter of more than 30 mm or limiting daily activities. Grade 3 pruritus was defined 
as having systemic pruritus. Grade 1 fever was defined as a temperature of more than 
37.0°C, and grade 3 fever was defined as a temperature of more than 39.0°C. Grade 3 
fatigue and weakness were defined as normal activities being weakened >50% with a 
strong influence on daily activities in addition to the prevention of working. Grade 3 
headache was defined as serious influence on daily activities, with response to the 
initial anaesthetic treatment. Grade 3 cough was defined as having a paroxysmal 
cough that could not be controlled via treatment. Grade 3 myalgia was defined as 
having severe muscular tenderness, with a strong influence on daily activities. Grade 
3 nausea and vomiting were defined as having nausea or vomiting 6 times within 24 
hours and no significant food intake, with intravenous infusion required. Grade 3 
diarrhoea was defined as having watery stools > 6 times/day or bloody diarrhoea, 
orthostatic hypotension, electrolyte imbalance, and >2 L intravenous infusion. A 
grade 3 allergic reaction was defined as extensive urticaria and angioedema.  
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†
 By mistake, one participant in the vaccine group was given the control vaccine for 
dose 1, and two participants in the control group were given the test vaccine for dose 
3. These three participants were classified into the vaccine group for safety analysis, 
according to the protocol. 
‡
 Unsolicited adverse events included any adverse events that occurred during the 
period from day 8 to day 30 after each vaccination and any adverse events that 
occurred within 7 days after each vaccination but that had not been listed on the diary 
card for registering solicited adverse events. A grade 3 unsolicited event was defined 
as a severe and significant limitation of daily activities that required help in daily life, 
medical treatment or hospitalization.  
§
 The data and safety monitoring board did not consider any of the serious adverse 
events, death or not, to be related to vaccination. All serious adverse events, 
categorized by organ system and treatment group, are provided in the Supplementary 
Table 7. 
|| A total of 6 participants died during the entire study. Of them, one participant in the 
vaccine group committed suicide by consuming poison at 13 days post the first 
injection, and one participant with a history of type 2 diabetes (for >10 years) in the 
vaccine group died from diabetic ketoacidosis at 14 months post the third injection. 
The other 4 participants died from traffic accidents at 3 to 24 months after their last 
injections. 
¶
 Some women became pregnant more than once. 
# There were four twins, two in the vaccine group and two in the control group. 
** One woman who received three doses of the HepE vaccine was diagnosed with 7+2 
weeks of pregnancy at 72 days after the last injection, and the foetus was found to 
have hydronephrosis. Her baby girl was born after the normal period of gestation by 
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Caesarean section, and the baby was then diagnosed with congenital ureter stenosis of 
the right kidney half a year later. Another baby boy born to a participant who received 
three doses of the HepE vaccine was diagnosed with heritable thalassemia. The data 
and safety monitoring board did not consider these events to be related to vaccination. 
††
 One participant became pregnant at 36 months after her third injection with the test 
HPV vaccine. At 28+6 weeks of pregnancy, due to a complication of severe pre-
eclampsia, a male infant with a body weight of 1.4 kilograms was delivered by 
Caesarean section. The newborn improved and was discharged after receiving one 
week of medical care and treatment. The data and safety monitoring board did not 
consider this event to be related to vaccination.  
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Figure titles and legends 
 
Figure 1. Study profile 
* By mistake, one participant in the vaccine group was given the control vaccine (the 
commercialized recombinant hepatitis E vaccine containing 30 μg of recombinant 
hepatitis E virus capsid protein absorbed to aluminium adjuvant) for dose 1, and two 
participants in the control group were given the test vaccine for dose 3. According to 
the protocol, these participants were retained in the randomly assigned group for 
efficacy analysis but were classified into the vaccine group for safety analysis. † 
Susceptible to infection by a relevant type of HPV is defined as negative for the 
corresponding type of neutralizing antibody on day 0 and negative for the 
corresponding type of HPV DNA from day 0 through month 7. PPS-E, per-protocol 
set for the pathological endpoint. PPS-PI, per-protocol set for the persistent infection 
endpoint. PPS-I, per-protocol set for the immune endpoint. PPS-P, per-protocol set for 
the immune persistence endpoint. 
 
Figure 2. Time until the development of high-grade genital lesions or persistent 
infection associated with HPV-16/18 in the susceptible population 
Panel A shows the accumulation of cases with high-grade genital lesions related to 
HPV-16/18 in the per-protocol set (PPS-E). Panel B shows the accumulation of cases 
with persistent infection related to HPV-16/18 in the per-protocol set (PPS-PI). Error 
bars represent 95% confidence intervals. The bars for the vaccine group were 
artificially moved slightly to the left to allow better discrimination from those for the 
control group. Of note, due to the closing calendar date for this interim analysis, a 
small number of participants were at risk at months 42 and 48. 
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Figure 3. The persistence of vaccine-induced type-specific IgG antibodies in 
women who were administered three doses of the assigned vaccine or control 
regimens 
The immune persistence of the vaccine was assessed in a subcohort containing 
susceptible participants who were seronegative for the relevant types of HPV at entry, 
who were DNA negative from day 0 to month 7, and who received three doses of the 
HPV vaccine or control HepE vaccine (PPS-P cohort). The positive samples were 
further quantified using references traceable to the WHO international standards for 
antibodies against HPV-16 (NIBSC code 05/134) or HPV-18 (NIBSC code 10/140), 
expressed in international units (IU). The lower detection limits of the eVLP-ELISAs 
were 3.1 IU/mL for HPV-16 antibodies and 2.0 IU/mL for HPV-18 antibodies. For 
calculating the geometric mean concentration (GMC) of the antibodies, antibody titres 
below the lower detection limit of the assay were given an arbitrary value of half the 
cutoff value. The bar showed the 95% confidence interval of the corresponding 
antibody level. 
 
 
 
 
 
 
 
 
 
 
 
  
